• Vincent Medical posted 1H2026 revenue of HK$481.6 million, up 7.1%, while profit attributable to owners fell 15.7% to HK$43.5 million.
• Basic earnings per share slipped to HK6.71 cents; interim dividend was cut to HK2.0 cents per share.
• Imaging disposables revenue rose 7.2% to HK$261.6 million, while respiratory sales edged down 1.9% to HK$124 million.
• Other products revenue climbed 38.8% to HK$82.9 million, while orthopaedic and rehabilitation revenue dropped 31.8% to HK$13.1 million.
• Trial operations at the new Kaiping R&D and production facility remain on track for end-2026, with phased commercial output from 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vincent Medical Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260909-12325795), on September 09, 2026, and is solely responsible for the information contained therein.